EUR 2.66
(1.33%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 106.9 Million EUR | 3.09% |
2022 | 103.69 Million EUR | 8.72% |
2021 | 95.38 Million EUR | 1.36% |
2020 | 94.1 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 107.78 Million USD | -6.18% |
2024 Q3 | 122.66 Million EUR | 10.83% |
2024 Q2 | 110.67 Million EUR | 10.34% |
2023 FY | 106.9 Million EUR | 3.09% |
2023 Q1 | 103.28 Million EUR | 0.0% |
2023 Q2 | 104.63 Million EUR | 1.31% |
2023 Q4 | 106.9 Million EUR | 4.57% |
2023 Q3 | 102.23 Million EUR | -2.3% |
2022 Q4 | - EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Atrys Health, S.A. | 629 Million EUR | 83.005% |
Biotechnologies Assets SA | 16.6 Million EUR | -543.692% |
Pharma Mar, S.A. | 341.22 Million EUR | 68.671% |
Laboratorios Farmaceuticos Rovi, S.A. | 799.88 Million EUR | 86.636% |